talquetamab side effects

In the phase 1 trial, 232 patients with relapsed or refractory myeloma were given talquetamab. Keep up with the story. In total 70% of patients experienced Cytokine Release Syndrome (CRS) but all events were minor. redness, pain, or swelling of the eye, eyelid, or inner lining of the eyelid. The . Emerging Strategies to Manage Relapsed and/or Refractory Multiple Myeloma. Clipboard, Search History, and several other advanced features are temporarily unavailable. Talquetamab (JNJ-64407564) is an investigational bispecific antibody. Last Updated: 12/19/2022 12:57:45 PM. This is a whole new era of cancer therapy, Dr. Chari said. This novel blood clot treatment doesn't increase bleeding risk, Why young women have more adverse outcomes after a heart attack than young men, Gut microbiome appears to fluctuate throughout the day and across seasons, One-hour endoscopic procedure could eliminate the need for insulin for type 2 diabetes, New clues to slow aging? Lots of liquids, smoothies, small bites, [and teaching them to] sit upright when they eat [and] wash everything down with liquidbecause it seems that dryness was just extending all the way down the upper gastrointestinal [GI] tract., A take home is the early treatment of oral candida, she concluded. Talquetamab: Uses, Interactions, Mechanism of Action - DrugBank Oncology On-The-Go Podcast: Multiple Myeloma Outcome Disparities, Trial Access. Dima D, Ullah F, Mazzoni S, Williams L, Faiman B, Kurkowski A, Chaulagain C, Raza S, Samaras C, Valent J, Khouri J, Anwer F. Cancers (Basel). Epub 2023 Feb 3. June 29, 2022. Talquetamab appears to have a have favorable risk/benefit profile in RRMM with durable responses and manageable toxicities. Bispecific Antibody Platform: Early Data in Relapsed and Refractory Please enable it to take advantage of the complete set of features! Approximately 74% of patients receiving 0.4 mg/kg of talquetamab weekly and 73% of those receiving 0.8 mg/kg every other week saw a measurable improvement of their cancer following treatment, the primary endpoint for the trials second phase. Drilling down into the data, there were 59% very good partial responses (VGPR) with the lower dose, along with . Results: View duration, location, compensation, and staffing details. Talquetamab is a bispecific antibody, a type of monoclonal antibody that redirects T cells to act against myeloma cells. But there are six trials recruiting! Dr. Chari explained: A complete response isnt actually a cure but its basically getting it down to a level where its undetectable. We need options for those patients, said Ajai Chari, a study author and hematologist from the Tisch Cancer Institute at Mount Sinai in New York, in a press conference held by ASH. . Methods: Xerostomia . Thus, combination therapies may both enhance activity and offer a favorable side-effect profile. The idea behind bispecific antibodies is they work to bridge immune cells with cancer cells. And this will us the idea that, for example, if you've had a BCMA-directed CAR T cell, you still could be treated with a bispecific such as talquetamab. More than 7 days . Learn more. Dose delays may also be an effective method of mitigating oral and dermatologic therapies, she concluded. Study results presented on Saturday and published in The New England Journal of Medicine suggest it could be the next promising drug to emerge in multiple myeloma an area already of intense drugmaker interest. Read on for details and takeaways from the meeting over the weekend: Like many new drug targets, its name is complicated and better off abbreviated. A new therapy that makes the immune system kill bone marrow cancer cells was successful in as many as 73 percent of patients in two clinical trials, according to researchers from The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai. Between the Lines Podcast: Updates in Use of Proteasome Inhibitors for Relapsed/Refractory Multiple Myeloma. Talquetamab: An Antibody for Multiple Myeloma It is graphic, but it prepared patients for what to expect.. The response rate observed in this cohort, which Dr Chari explained is higher than that of most currently accessible therapies, suggests talquetamab could offer a viable option for patients with hard-to-treat myeloma, offering a chance to extend patient . At the data-cutoff date, 232 patients had received talquetamab (102 intravenously and 130 subcutaneously). At least he plans to, but we have zero CAR-T capacity and no idea when the situation . making it an attractive therapeutic target. Talquetamab for Multiple Myeloma Clinical Trial 2023 | Power I lost a lot of sleep over this, Aronson shared, noting that her patients were distressed by these AEs. Track your myeloma and find treatment options, Journal your myeloma story in video, audio and writing, Learn from 150+ myeloma experts in video lessons, Find a free personal coach to help navigate your myeloma, Join our new social media app for myeloma patients, Tackle challenges and crush your fitness goals together, Stay up-to-date with thousands of myeloma news articles, Listen to one-on-one interviews with experts on clinical trials, Attend in-person meetings with myeloma experts, Join community groups with other patients and caregivers, Answer survey questions to advance myeloma research, Find answers to commonly asked questions when navigating HealthTree services. Good oral care is really key, she said, adding that the standard recommendations to prevent mucositis for patients about to undergo transplant are relevant with this patient population as well to reduce the bioburden in the mouth. The most common AEs related to treatment with talquetamab include cytokine release syndrome (CRS), neurotoxicity, cytopenia, infections, skin and nail disorders, and oral toxicities. More Than 70% of Heavily Pretreated Patients Taking Talquetamab for Off-the-shelf immunotherapy could offer new hope for patients with hard The side effects are troubling, some require hospitalization, especially because of infections. Apalutamide Elicits PSA Response, Lowers Progression to Castration Resistant Disease in mCSPC, Nurse Investigators on Using Weighted Blankets to Alleviate Anxiety During Cancer Treatment Infusions, Best Practices on Managing AEs With Darolutamide Plus ADT/Docetaxel in mHPSC, Jessica MacIntyre on Improving LLS Referrals For Patients With Hematologic Malignancies. or who could not receive these therapies without unacceptable side effects. Each entry includes links to find associated clinical trials. ASCO: J&J's subcutaneous bispecifics tackle multiple myeloma in phase 1 Few side effects, though. Scientists use genetic rewiring to increase lifespan of cells. Background: In addition, several other studies are underway to assess the use of talquetamab in combination with other existing and investigational multiple myeloma therapies, which could allow patients to have similar or improved benefits, potentially in earlier stages of treatment. The primary end points - the frequency and type of dose-limiting toxic effects (study part 1 only), adverse events, and laboratory abnormalities - were assessed in order to select the recommended doses for a phase 2 study. Nurses Call for More Research on Nutrition Challenges for Patients With AML/MDS. In July 2012, Genmab entered into a collaboration with Janssen Biotech, Inc. (Janssen) to create and develop bispecific antibodies using Genmab's DuoBody technology platform. Accessibility Talquetamab, a G protein-coupled receptor family C group 5 member D X CD3 bispecific antibody, in relapsed/refractory multiple myeloma: updated efficacy and safety results from MonumenTAL-1. The study participants had all been previously treated with at least three different therapies without achieving lasting remission, suggesting talquetamab could offer new hope for patients with hard-to-treat multiple myeloma. Side effects were relatively frequent, but typically mild.

County Hotel, Llandudno, Articles T